Filter posts

Despite Low Funding, Biotech Productivity Remains High In 2013

At the 2013 BIO CEO & Investor Conference, John Milligan, President and COO of Gilead …

Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech

After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most …

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called …

Word on the Street – Biotech Stocks Only Have Room to Go Up

The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively …

The Year Ahead for Business Development Events

2013 is officially here (insert stale End-of-the-World joke). And as such, planning has been in …

Industry Outlook in Anticipation of the 2012 BIO International Convention

This month, BIO wrapped the 14th Annual CEO & Investor Conference in New York City …

BIO CEO 2012 Opening Remarks

The 14th Annual BIO CEO & Investor Conference started with a busy turnout Monday at …

Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation

The Tuesday plenary luncheon at the 2012 BIO CEO & Investor Conference featured a panel …

Fireside Chat with Dr. Mikael Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat …

Picks and Pans – The Buy-Side View for 2012

What’s the forecast for biotech in 2012? Do investors think it is a good time …